
Join to view full profile
1500 Duarte RdDuarte, CA 91010
Phone+1 626-359-8111
Fax+1 626-408-3911
Dr. Mortimer is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified medical oncologist with specialization in breast and women's cancers. I have been part of City of Hope team since 2007 and am currently the vice chair and professor of the Department of Medical Oncology and Therapeutic Research and co-director of the Breast Cancer Program.
I love working with women; they’re amazing people. They get a diagnosis that is, at times, potentially fatal, and manage to get through it while still taking care of their families and kids, coming out the other side as stronger people.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 1980 - 1982
Cleveland Clinic FoundationResidency, Internal Medicine, 1977 - 1980
Loyola University Chicago Stritch School of MedicineClass of 1977
Certifications & Licensure
CA State Medical License 2004 - 2028
VA State Medical License 2002 - 2006
OH State Medical License 1979 - 1982
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Feb 28
- Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2011 Apr 20
- Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid Start of enrollment: 2012 Sep 14
Publications & Presentations
PubMed
- Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer.Nikita V Baclig, Madhuri Chengappa, Andrew J Soliman, Saya Jacob, Alexis LeVee
Clinical Breast Cancer. 2026-07-20 - GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study.Rebecca A Nelson, Ying-Chuen Lai, Sung H Kil, Hayley S Lee, Joanne Mortimer
The Oncologist. 2026-07-08 - GLP-1 Targeting Agents Impair Chemoimmunotherapy Effectiveness in Triple-Negative Breast Cancer.Bethania Santos, Maycon Marção, Ishrat Durdana, Brian Lee, Lavanya Vumma
Research Square. 2026-01-09
Journal Articles
- ERα-Mediated Cell Cycle Progression Is an Important Requisite for CDK4/6 Inhibitor Response in HR+ Breast CancerJoanne Mortimer, Laura Kruper, Raju Pillai, George Somlo, Yuan Yuan, Oncotarget
Press Mentions
Better Survival in BRCA-Mutated Breast Cancer with Neoadjuvant Olaparib-Chemo ComboMay 13th, 2025
Why Black Women Are More Likely to Die from Breast CancerJune 10th, 2021
Sanofi’s, AstraZeneca’s and Radius’ Oral SERDs Could Establish Clinical Worth in ER+ Breast Cancer by Showing Similar Efficacy to Faslodex, Experts SayApril 6th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









